The hypothesis was to check whether baseline anti-E1E2 antibodies were correlated with the on-treatment viral kinetics and could predict virological outcome in treatment-experienced HCV-infected cirrhotic patients receiving protease inhibitor-based triple therapy.
Study Type
OBSERVATIONAL
Enrollment
19
Cohort of patients who received triple therapy combining pegylated-interferon/ribavirin + first generation protease inhibitor boceprevir or telaprevir as part of routine clinical practice
Hôpital de la Croix Rousse
Lyon, France
Proportion of patients with positive anti-E1E2 antibody level at treatment initiation
Anti-E1E2 antibody levels were determined as previously described (Ndongo et al. Hepatology 2010;52:1531-42) using optical densities obtained after dilution of patients' serum samples at 1/250 and 1/500. Samples with anti-E1E2 levels above 950 (OD value× 1000) were considered positive.
Time frame: Baseline (initiation of treatment)
Kinetic of Quantification of hepatitis C viral load (HCV RNA)
Viral load was assessed at baseline (initiation of treatment), and at week 4, 12, 24, 36, and 48 of therapy and 12 weeks after the end of treatment.
Time frame: baseline (initiation of treatment), at week 4, 12, 24, 36, 48 of therapy, at 12 weeks after the end of treatment.
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.